On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic colorectal cancer; metastatic nonsquamous NSCLC; glioblastoma multiform; metastatic RCC; recurrent/metastatic cervical cancer; and epithelial ovarian cancer. Till now, this is the 4th bevacizumab biosimilar that got FDA approval after Amgen’s, Pfizer’s and Amneal’s biosimilars.
.png)